Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Discovery Grants Program - Individual

Dalhousie University

$32,000.00

Identification of new drugs and the evaluation of vaccines for treating and preventing canine distemper in dogs and raccoons

EF 2019-20

Résumé
Canine distemper virus (CDV) is a morbillivirus that is closely related to measles virus (MeV). These viruses are highly contagious and infect lymphocytes, airway epithelial cells, and cells of the neurological system. There have been recent outbreaks of CDV in urban populations of raccoons in Halifax and Toronto. In addition, there are global concerns originating in China, where CDV was observed to jump from dogs into macaques at various primate centres. Our laboratory discovered the cellular receptors for morbilliviruses (SLAMF1, Nectin-4, and CD46). This application represents a new venture into antiviral drugs and the evaluation of vaccines directed against CDV. We propose to use ferret and a SLAMF1 transgenic model to evaluate drugs and vaccines. Ferrets are extremely susceptible to CDV and die within 2 weeks of contracting disease. We also have found that a single mutation in the CDV-H receptor binding protein permits the virus to replicate in our human SLAMF1 transgenic mouse model. In Aim 1 we propose to test the same mouse with wild type CDV strains including neurotropic Snyder Hill virus and local raccoon isolates. Infected mice will be dissected and tissue will be cryo-sectioned and analyzed for virus using immune fluorescence microscopy and RT-PCR. We will use the ferret and mouse models to evaluate new antiviral drugs directed against CDV in Aim 2. There are no therapeutic drugs for treating morbillivirus infections, but I previously discovered a small peptide Z-D-Phe-L-Phe Gly which blocked MeV-mediated membrane fusion and entry into the host cell [Richardson et al. (1980) Virology 105: 205-222]. A small molecular analogue to this peptide (AS48) has been synthesized and both molecules target a similar hydrophobic cavity in the MeV fusion (F) protein [Ha et al. (2017) J. Virol. 91(23):e01026-17]. Similar molecules which inhibit the F protein of CDV will be identified using a chemical library at the Li Ka Shing Virology Institute, Edmonton. Another target for antiviral drugs directed against CDV is the viral RNA polymerase (L). One lead compound (ERDRP-0519) appears effective against MeV and we propose to identify compounds that target the CDV polymerase. Aim 3 addresses a perennial problem with CDV vaccines characterized by vaccine-related encephalitis. The Rockborn vaccine is particularly prone to this debility. The safer Onderstepoort vaccine is attenuated exclusively in eggs, while the problematic Rockborn strain is propagated in mammalian cell culture. We propose to assess receptor usage of various strains of CDV using CHO, CHO-CD46, CHO-dogSLAMF1, CHO-dogNectin-4, CHO-chickNectin-4, and CHO-PVRL2 cell lines. We will study the poorly understood process of virus attenuation by studying vaccine and wild type CDV infections in canine peripheral blood lymphocytes and primary canine tracheal/bronchial epithelial cells. Infectious particle formation, viral protein synthesis, and interferon production by these cells will be evaluated.
Programme
Discovery Grants Program - Individual
Bénéficiaire
Emplacement
Nova Scotia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
RGPIN-2019-06612
Name nom
Richardson, Christopher
Department département
Microbiology and Immunology
Organization id
79
Institution établissement
Dalhousie University
Province en
Nova Scotia
Province fr
Nouvelle-Écosse
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2019
Competition year année de concours
2019
Award amount
32000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
DISCOVERY RESEARCH
Group fr
RECHERCHE AXÉE SUR LA DÉCOUVERTE
Committee code
1501
Committee name en
Genes, Cells and Molecules
Committee name fr
Gènes, cellules et molécules
Area of application code
102
Area of application group en
Agriculture and primary food production
Area of application group fr
Agriculture et produits alimentaires primaires
Area of application en
Animal management (animal diseases, breeding)
Area of application fr
Gestion des animaux (maladies animales, reproduction)
Research subject code
5202
Research subject group en
Microbiology
Research subject group fr
Microbiologie
Research subject en
Virology
Research subject fr
Virologie
Installment
inst:1 - 1
Partie
1
Nb partie
1
Application title
Identification of new drugs and the evaluation of vaccines for treating and preventing canine distemper in dogs and raccoons
Keyword
NSERC
Application summary
Canine distemper virus (CDV) is a morbillivirus that is closely related to measles virus (MeV). These viruses are highly contagious and infect lymphocytes, airway epithelial cells, and cells of the neurological system. There have been recent outbreaks of CDV in urban populations of raccoons in Halifax and Toronto. In addition, there are global concerns originating in China, where CDV was observed to jump from dogs into macaques at various primate centres. Our laboratory discovered the cellular receptors for morbilliviruses (SLAMF1, Nectin-4, and CD46). This application represents a new venture into antiviral drugs and the evaluation of vaccines directed against CDV. We propose to use ferret and a SLAMF1 transgenic model to evaluate drugs and vaccines. Ferrets are extremely susceptible to CDV and die within 2 weeks of contracting disease. We also have found that a single mutation in the CDV-H receptor binding protein permits the virus to replicate in our human SLAMF1 transgenic mouse model. In Aim 1 we propose to test the same mouse with wild type CDV strains including neurotropic Snyder Hill virus and local raccoon isolates. Infected mice will be dissected and tissue will be cryo-sectioned and analyzed for virus using immune fluorescence microscopy and RT-PCR. We will use the ferret and mouse models to evaluate new antiviral drugs directed against CDV in Aim 2. There are no therapeutic drugs for treating morbillivirus infections, but I previously discovered a small peptide Z-D-Phe-L-Phe Gly which blocked MeV-mediated membrane fusion and entry into the host cell [Richardson et al. (1980) Virology 105: 205-222]. A small molecular analogue to this peptide (AS48) has been synthesized and both molecules target a similar hydrophobic cavity in the MeV fusion (F) protein [Ha et al. (2017) J. Virol. 91(23):e01026-17]. Similar molecules which inhibit the F protein of CDV will be identified using a chemical library at the Li Ka Shing Virology Institute, Edmonton. Another target for antiviral drugs directed against CDV is the viral RNA polymerase (L). One lead compound (ERDRP-0519) appears effective against MeV and we propose to identify compounds that target the CDV polymerase. Aim 3 addresses a perennial problem with CDV vaccines characterized by vaccine-related encephalitis. The Rockborn vaccine is particularly prone to this debility. The safer Onderstepoort vaccine is attenuated exclusively in eggs, while the problematic Rockborn strain is propagated in mammalian cell culture. We propose to assess receptor usage of various strains of CDV using CHO, CHO-CD46, CHO-dogSLAMF1, CHO-dogNectin-4, CHO-chickNectin-4, and CHO-PVRL2 cell lines. We will study the poorly understood process of virus attenuation by studying vaccine and wild type CDV infections in canine peripheral blood lymphocytes and primary canine tracheal/bronchial epithelial cells. Infectious particle formation, viral protein synthesis, and interferon production by these cells will be evaluated.